ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025
Pediatric multiple sclerosis: Improving outcome through high-efficacy therapies.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prognostic factors in paediatric-onset multiple sclerosis: a narrative review.Journal of neurology · 2026Review
- Treatment persistence in paediatric-onset multiple sclerosis: A Swedish nationwide registry study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Special Edition: Therapeutic advances in multiple sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- Multimodal machine learning for distinguishing pediatric multiple sclerosis from non-inflammatory conditions using optical coherence tomography.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric-onset multiple sclerosis (POMS) refers to multiple sclerosis occurring in individuals under 18 years of age. It is characterized by poor cognitive outcomes and a more inflammatory course, more frequent clinical relapses, and a greater number of MRI lesions compared to adult-onset MS (AOMS). Prompt recognition of multiple sclerosis in this population is essential, as early intervention with disease-modifying therapies may change the trajectory of disease progression. In this paper, we will review diagnostic criteria for pediatric multiple sclerosis, differential diagnosis, and current and emerging therapeutic approaches. While a number of DMTs are approved for adult MS, few are approved for pediatric use. Many of these DMTs are used off-label, with real-world evidence demonstrating their effectiveness and safety. The review evaluates existing evidence for the use of these therapies in pediatric populations, with an emphasis on both existing clinical trials and real-world data that supports their use. In addition, we will briefly highlight ongoing clinical trials and emerging therapies for POMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.